Valuation: GI Dynamics, Inc.

Market Cap 4L 4L 4L 3L 6L 4.23Cr 6L 42.44L 16.65L 2.07Cr 16.55L 16.18L 7.13Cr P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 32.79L 28.66L 26.49L 24.48L 46.09L 32Cr 46.93L 3.16Cr 1.24Cr 15Cr 1.23Cr 1.2Cr 53Cr EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Chairman 67 21/10/2020
Director/Board Member - 20/10/2020
Director/Board Member - -

Financials

2019 2020
Net sales - -
Net income -1.73Cr -1.51Cr -1.4Cr -1.29Cr -2.44Cr -166.49Cr -2.48Cr -17Cr -6.55Cr -82Cr -6.51Cr -6.37Cr -280.71Cr -1.11Cr -97.32L -89.96L -83.12L -1.57Cr -106.97Cr -1.59Cr -11Cr -4.21Cr -52Cr -4.18Cr -4.09Cr -180.35Cr
Net Debt 28.87L 25.23L 23.32L 21.55L 40.58L 28Cr 41.31L 2.78Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr 28.39L 24.81L 22.94L 21.19L 39.9L 27Cr 40.63L 2.74Cr 1.07Cr 13Cr 1.07Cr 1.04Cr 46Cr
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-